Smahel Michal, Tejklova Pavla, Smahelova Jana, Polakova Ingrid, Mackova Jana
Department of Experimental Virology, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
Cancer Immunol Immunother. 2008 Jun;57(6):823-31. doi: 10.1007/s00262-007-0418-9. Epub 2007 Oct 26.
Infection with high-risk types of human papillomavirus (HPV) can cause the development of malignant tumors. To study mechanisms responsible for immune escape of tumor cells infected with HPV16, we previously used mouse oncogenic TC-1 cells producing HPV16 E6 and E7 oncoproteins to derive TC-1 clones resistant to immunization against E7. We have found immunoresistance of the clones to correlate with the point mutation in the E7 oncogene, which resulted in the N53S substitution in the immunodominant epitope RAHYNIVTF (aa 49-57). Here, we have shown that this mutation reduced stabilization of H-2D(b) molecules on RMA-S cells and eliminated immunogenicity of E7. The resistance of TC-1 clones was E7-specific as immunization against E6 inhibited tumor growth. Transduction of the TC-1/F9 clone carrying the mutated epitope with the wild-type E7 gene restored susceptibility to immunization against E7. Our results suggest that mutagenesis of tumor antigens can lead to the escape of malignant cells and should be considered in the development and evaluation of cancer immunotherapy.
感染高危型人乳头瘤病毒(HPV)可导致恶性肿瘤的发生。为了研究HPV16感染的肿瘤细胞免疫逃逸的机制,我们之前使用产生HPV16 E6和E7癌蛋白的小鼠致癌TC-1细胞来获得对E7免疫接种具有抗性的TC-1克隆。我们发现这些克隆的免疫抗性与E7癌基因中的点突变相关,该突变导致免疫显性表位RAHYNIVTF(第49 - 57位氨基酸)中的N53S替换。在此,我们表明该突变降低了RMA-S细胞上H-2D(b)分子的稳定性,并消除了E7的免疫原性。TC-1克隆的抗性是E7特异性的,因为针对E6的免疫接种抑制了肿瘤生长。用野生型E7基因转导携带突变表位的TC-1/F9克隆可恢复对E7免疫接种的敏感性。我们的结果表明,肿瘤抗原的诱变可导致恶性细胞逃逸,在癌症免疫治疗的开发和评估中应予以考虑。